摘要
基因治疗为高血压的长效 (数周、数月或数年 )治疗提供了可能。高血压病基因治疗的临床前研究运用了两种策略 :1 将功能基因导入体内增加扩血管蛋白物质。 2 将反义脱氧寡核苷酸 (AS ODN)或反义DNA导入体内 ,抑制缩血管基因的功能。为达到此目的 ,已建立了两种基因导入方法 :1 将AS ODN直接注射入人体或附着于阳离子脂质体注入。 2 利用含完整DNA的病毒载体。目前 ,临床前研究资料提示高血压病的基因治疗是可行的 ,但在临床用于人的基因治疗前还需进行深入研究 ,一些理论问题还尚待解决。
Gene therapy offers potential longer lasting antihypertensive effects (weeks, months or years). Preclinical studies on gene therapy for hypertension have two strategies: a) gene transfer to increase vasodilator proteins. b) antisense oligodeoxynucleotides (AS ODN) or antisense DNA delivery to inhibit genes associated with vasoconstrictive properties. To do this, two approaches of delivering genes have been developed :a) AS ODN by direct injection or in cationic liposomes; b) full DNA in viral vectors .In conclusion, the preclinical data indicate that gene therapy for hypertension is possible. Further studies are necessary and before its clinical application.
出处
《基础医学与临床》
CSCD
北大核心
2002年第6期494-497,共4页
Basic and Clinical Medicine
